Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · GKB OPHTHALMICS LTD. · 29 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
GKB OPHTHALMICS LTD.
NSE: GKB · BSE: 533212
NSE: GKB · BSE: 533212
Healthcare › Healthcare › Healthcare Equipment & Supplies › Medical Equipment & Supplies
GKB OPHTHALMICS LTD.
StateQ4 FY26 filed
Last close · 28 Oct 2026₹60.50
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA9.4 · 0.56 · 4.3
GKB OPHTHALMICS LTD. is a Healthcare Equipment & Supplies company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 71 | 75 | 88 | 109 | 149 |
| EBITDA (ex other income) | 5 | 4 | 1 | (3) | 7 |
| margin % | 6.8 | 4.9 | 0.7 | (2.6) | 4.6 |
| Owners' profit | 1 | (0) | (3) | (7) | 1 |
| EPS, as reported (₹) | 2.53 | (0.33) | (5.58) | (13.98) | 2.42 |
| ROE % · ROCE % | 2.9 · 4.7 | 0.2 · 2.5 | (4.6) · (1.2) | (12.5) · (7.2) | 5.5 · 9.6 |
| Debt / equity (x) | 0.17 | 0.17 | 0.18 | 0.26 | 0.21 |
| Cash from operations | 5 | (3) | 4 | (3) | (4) |
| Capex | (5) | (2) | (2) | (2) | (1) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · GKB OPHTHALMICS LTD. · 29 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26 | 26 | 26 | 31 | 32 | 30 | 57 | 30 |
| Profit before tax | 0 | (1) | (2) | (4) | (1) | 2 | 1 | 1 |
| Net profit | 0 | (1) | (2) | (4) | (1) | 2 | 1 | 1 |
| EPS (₹) | (0.50) | (2.41) | (4.03) | (7.03) | 2.02 | 3.17 | 0.88 | 0.38 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| POLY MEDICURE LIMITED | 15,101 | 47.9 | 4.80 | 27.7 | 10.2 | 12.6 | 19.0 | 30.2 |
| FISCHER MEDICAL VENTURE L | 1,725 | 11.0 | 4.48 | 32.2 | 8.1 | 11.3 | — | 15.5 |
| TARSONS PRODUCTS LIMITED | 1,623 | 146.0 | 2.56 | 14.1 | 2.3 | 2.4 | — | 29.0 |
| LAXMI DENTAL LIMITED | 995 | 32.0 | 4.08 | 21.4 | 11.8 | 11.0 | — | 22.3 |
| Hemant Surgical Industries Lim | 750 | 28.7 | — | — | — | 16.7 | — | — |
| FABTECH TECHNOLOGIES LTD | 560 | 9.1 | 1.33 | 9.0 | 9.1 | 10.7 | — | 9.9 |
| Prevest Denpro Limited | 456 | 15.4 | — | — | — | 21.9 | — | — |
| NURECA LIMITED | 287 | 58.9 | 1.59 | 34.6 | 1.2 | 2.7 | (7.2) | 13.0 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 9.4 | 21.3 | 3 of 16 | 87% |
| P/B | 0.6 | 2.6 | 1 of 11 | 100% |
| ROCE | 5.2 | 11.3 | 13 of 17 | 25% |
| ROE | 5.5 | 8.1 | 8 of 11 | 30% |
| Debt / Equity | 0.2 | 0.1 | 9 of 11 | 20% |
| EBITDA margin | 8.1 | 16.7 | 11 of 11 | 0% |
| Revenue growth | (4.0) | 13.9 | 12 of 13 | 8% |
| Profit growth | 127.1 | 75.5 | 5 of 10 | 56% |
| Market cap | 31 | 164 | 15 of 17 | 13% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · GKB OPHTHALMICS LTD. · 29 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 8 Oct 2026 · Reg 74(5) certificate filed for quarter ended Sep 30, 2026 | compliance | minimal | — | — |
| 28 Sept 2026 · GKB Ophthalmics closes trading window ahead of Q2 results | compliance | minimal | — | — |
| 22 Sept 2026 · 44th AGM Minutes: All 7 resolutions approved; no dividend for FY26 | board shareholder meetings | low | — | — |
| 26 Aug 2026 · GKB Ophthalmics 44th AGM held Aug 25 2026; all 7 resolutions passed | board shareholder meetings | low | — | — |
| 25 Aug 2026 · GKB Ophthalmics 44th AGM held on Aug 25, 2026 | board shareholder meetings | low | — | — |
| 14 Aug 2026 · GKB Ophthalmics Q1 FY27 results published in newspapers | compliance | minimal | — | — |
| 1 Aug 2026 · GKB Ophthalmics 44th AGM notice published; dividend record date Aug 10 | compliance | minimal | — | — |
| 31 Jul 2026 · Annual Report FY 2025-26 and 44th AGM notice sent to shareholders | compliance | minimal | — | — |
| 31 Jul 2026 · Book Closure for 44th AGM from Aug 19-25, 2026; No Dividend | board shareholder meetings | low | — | — |
| 31 Jul 2026 · Annual Report FY 2025-26 and 44th AGM Notice submitted | compliance | minimal | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in